Longeveron (LGVN) Competitors $0.76 +0.01 (+1.41%) As of 02:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LGVN vs. LTRN, PEPG, NBRV, RNXT, ATHE, AADI, ANVS, GRCE, JSPR, and IPSCShould you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Lantern Pharma (LTRN), PepGen (PEPG), Nabriva Therapeutics (NBRV), RenovoRx (RNXT), Alterity Therapeutics (ATHE), Aadi Bioscience (AADI), Annovis Bio (ANVS), Grace Therapeutics (GRCE), Jasper Therapeutics (JSPR), and Century Therapeutics (IPSC). These companies are all part of the "pharmaceutical products" industry. Longeveron vs. Its Competitors Lantern Pharma PepGen Nabriva Therapeutics RenovoRx Alterity Therapeutics Aadi Bioscience Annovis Bio Grace Therapeutics Jasper Therapeutics Century Therapeutics Longeveron (NASDAQ:LGVN) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Which has higher earnings & valuation, LGVN or LTRN? Longeveron has higher revenue and earnings than Lantern Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLongeveron$2.07M5.58-$15.97M-$6.28-0.12Lantern PharmaN/AN/A-$20.78M-$1.78-2.30 Is LGVN or LTRN more profitable? Lantern Pharma has a net margin of 0.00% compared to Longeveron's net margin of -894.40%. Longeveron's return on equity of -95.91% beat Lantern Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Longeveron-894.40% -95.91% -79.69% Lantern Pharma N/A -99.89%-81.58% Does the media favor LGVN or LTRN? In the previous week, Lantern Pharma had 5 more articles in the media than Longeveron. MarketBeat recorded 6 mentions for Lantern Pharma and 1 mentions for Longeveron. Longeveron's average media sentiment score of 1.89 beat Lantern Pharma's score of -0.06 indicating that Longeveron is being referred to more favorably in the media. Company Overall Sentiment Longeveron Very Positive Lantern Pharma Neutral Which has more risk and volatility, LGVN or LTRN? Longeveron has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Do analysts recommend LGVN or LTRN? Longeveron currently has a consensus target price of $7.67, suggesting a potential upside of 906.12%. Lantern Pharma has a consensus target price of $25.00, suggesting a potential upside of 509.76%. Given Longeveron's higher probable upside, research analysts plainly believe Longeveron is more favorable than Lantern Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Lantern Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in LGVN or LTRN? 10.0% of Longeveron shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 11.2% of Longeveron shares are owned by company insiders. Comparatively, 8.5% of Lantern Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryLongeveron beats Lantern Pharma on 9 of the 14 factors compared between the two stocks. Get Longeveron News Delivered to You Automatically Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LGVN vs. The Competition Export to ExcelMetricLongeveronMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.57M$3.14B$5.75B$10.26BDividend YieldN/A2.36%5.88%4.63%P/E Ratio-0.1221.3577.0126.57Price / Sales5.58458.94528.65122.51Price / CashN/A45.4037.2060.49Price / Book0.529.6813.966.34Net Income-$15.97M-$53.02M$3.29B$270.99M7 Day Performance-4.75%1.58%1.38%2.67%1 Month Performance0.26%5.20%5.13%7.23%1 Year Performance-62.09%9.53%84.67%27.97% Longeveron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LGVNLongeveron3.269 of 5 stars$0.76+1.7%$7.67+906.1%-63.6%$11.57M$2.07M-0.1220Positive NewsLTRNLantern Pharma2.0683 of 5 stars$4.06-5.8%$25.00+515.8%+9.0%$46.54MN/A-2.2820News CoverageGap DownPEPGPepGen3.0042 of 5 stars$1.49+6.4%$7.67+414.5%-78.7%$45.92MN/A-0.5030Gap UpNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070RNXTRenovoRx2.3553 of 5 stars$1.14-8.1%$7.50+557.9%+18.9%$45.44M$40K-3.006Short Interest ↑Gap UpATHEAlterity Therapeutics2.4954 of 5 stars$5.17+2.0%$12.00+132.1%+242.3%$44.96MN/A0.0010News CoverageGap UpHigh Trading VolumeAADIAadi BioscienceN/A$1.82+0.6%N/A-1.1%$44.95M$25.07M-0.8040ANVSAnnovis Bio2.1178 of 5 stars$2.34+2.1%$17.33+641.4%-70.3%$44.62MN/A-1.153News CoverageGRCEGrace Therapeutics2.9216 of 5 stars$3.24+1.3%$12.00+270.4%N/A$44.25MN/A-3.77N/AJSPRJasper Therapeutics3.4696 of 5 stars$2.65-2.6%$28.75+984.9%-89.4%$44.21MN/A-0.4420IPSCCentury Therapeutics2.0594 of 5 stars$0.51+1.1%$3.75+634.9%-69.2%$43.60M$6.59M-1.76170 Related Companies and Tools Related Companies LTRN Alternatives PEPG Alternatives NBRV Alternatives RNXT Alternatives ATHE Alternatives AADI Alternatives ANVS Alternatives GRCE Alternatives JSPR Alternatives IPSC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LGVN) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longeveron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LGVN Stock Alerts